

## Pathophysiological Insights and Therapeutic Approaches in Ichthyosis Vulgaris: A Comprehensive Review

Saulo Emmanuel Gomez de Alba<sup>1</sup>, Luis Adrián Flores Chávez<sup>2</sup>, Rebeca Álvarez Fernández<sup>3</sup>, María Fernanda Romano Castañeda<sup>4</sup>, Leonardo Ramírez Nucamendi<sup>5</sup>, Paola Lizbeth Zamudio Naranjo<sup>6</sup>

<sup>1,2,3,4,5,6</sup> Universidad Autónoma de Guadalajara, Guadalajara, Jalisco.

### ABSTRACT

Ichthyosis vulgaris, a rare hereditary skin disorder, poses a significant clinical challenge due to its complex pathogenesis and clinical variability. This comprehensive review aims to provide an in-depth understanding of the underlying pathophysiological aspects of ichthyosis vulgaris, with a focus on the X-linked variant (X-Linked Ichthyosis, XLI). We will discuss the genetic foundations, molecular mechanisms involved in skin barrier dysfunction, and the characteristic clinical presentation of this condition. Furthermore, current and emerging treatment options, including pharmacological therapies and gene therapy, will be reviewed, highlighting the latest advancements in ichthyosis vulgaris research. This review will offer crucial insights for clinicians, geneticists, and scientists interested in comprehending and managing this hereditary skin disorder.

**KEYWORDS:** ichthyosis, vulgaris, skin, disorder.

### ARTICLE DETAILS

**Published On:**  
**14 October 2023**

**Available on:**

<https://ijmscr.org/>

### INTRODUCTION

Ichthyosis vulgaris, a rare yet debilitating skin disorder, encompasses a heterogeneous group of genetic disorders characterized by abnormal epidermal formation and desquamation. Within this family of conditions, X-linked ichthyosis (XLI) has been a particularly studied variant due to its relatively higher prevalence compared to other forms of ichthyosis. The molecular etiology of XLI has been the subject of intensive research in recent years, leading to significant advances in our understanding of the underlying pathogenesis.<sup>1</sup>

In this context, this review seeks to delve deeper into the understanding of ichthyosis vulgaris, with a specific focus on the XLI variant. We will begin by discussing the genetic foundations of the disease, highlighting mutations in the STS gene leading to steroid sulfatase deficiency and, ultimately, lipid accumulation in the epidermis. Subsequently, we will explore the molecular mechanisms behind skin barrier dysfunction and the formation of the characteristic scales observed in XLI patients.<sup>1</sup>

Furthermore, we will comprehensively review the clinical variability associated with this condition, from milder forms to more severe ones, highlighting key clinical and dermatological implications. Finally, we will delve into

current and emerging therapeutic options, ranging from traditional pharmacological approaches to innovative gene therapies that hold revolutionary promise in treating ichthyosis vulgaris.<sup>1</sup>

In summary, this comprehensive review will provide an in-depth understanding of ichthyosis vulgaris, with a special focus on the XLI variant, and will serve as an essential resource for clinicians, geneticists, and scientists aiming to enhance their comprehension and management of this complex hereditary skin disorder.<sup>1</sup>

### INCIDENCE AND PREVALENCE

Estimating the true incidence and prevalence of ichthyosis vulgaris is a complex endeavor due to its variable clinical expression, often milder phenotypes remaining undiagnosed. It is generally considered an infrequent condition, with prevalence estimates ranging from 1 in 250 to 1 in 1,000 live births in various populations. These rates may fluctuate depending on the geographical region and ethnic background, with higher frequencies reported in specific populations, such as those with Northern European ancestry. The condition typically manifests in early childhood and may persist throughout life, although its severity can vary considerably.<sup>2</sup>

# Pathophysiological Insights and Therapeutic Approaches in Ichthyosis Vulgaris: A Comprehensive Review

## GENETIC UNDERPINNINGS

Ichthyosis vulgaris is most commonly inherited in an autosomal dominant manner, primarily attributed to mutations in the filaggrin gene (FLG), situated on chromosome 1q21. Filaggrin is a pivotal protein in epidermal differentiation and the formation of the skin barrier. Mutations in the FLG gene result in reduced or absent filaggrin production, leading to compromised skin barrier function and the hallmark dry, scaly skin of ichthyosis vulgaris. Genotype-phenotype correlations have revealed that specific FLG mutations can influence the severity and clinical presentation of the disorder.<sup>2</sup>

## GEOGRAPHICAL VARIATIONS

Epidemiological studies have unveiled geographic variations in the prevalence of ichthyosis vulgaris, with higher rates reported in regions with a history of consanguinity or populations with a higher prevalence of specific FLG mutations. Northern European countries, including Scandinavia and the United Kingdom, have reported increased frequencies of the condition, aligning with the distribution of FLG mutation carriers in these areas. Conversely, populations in regions with less genetic homogeneity tend to exhibit lower prevalence rates.<sup>2</sup>

## DEMOGRAPHIC FACTORS AND PREDISPOSING ELEMENTS

Demographic factors such as age, gender, and family history can influence the epidemiology of ichthyosis vulgaris. The condition often presents in infancy or early childhood, affecting both males and females with equal likelihood. Family history plays a significant role, as individuals with affected first-degree relatives have a higher risk of inheriting the condition. Additionally, environmental factors, such as climate and humidity levels, can impact the clinical severity of ichthyosis vulgaris, with dry, cold climates exacerbating symptoms.<sup>3</sup>

The epidemiology of ichthyosis vulgaris is a multifaceted subject encompassing incidence, prevalence, genetic determinants, geographical variations, and demographic influences. Understanding the epidemiological intricacies of this rare dermatological disorder is essential for healthcare practitioners, researchers, and policymakers alike. By delving into the complex interplay of genetic and environmental factors, we can enhance our grasp of the global distribution of ichthyosis vulgaris and, consequently, improve diagnostic and therapeutic strategies for affected individuals. Further research and international collaboration are pivotal in unraveling the full extent of this condition's epidemiological nuances.<sup>3</sup>

## CLINICAL MANIFESTATIONS

Ichthyosis vulgaris, a hereditary disorder of keratinization, manifests with a wide spectrum of clinical features, primarily characterized by epidermal hyperkeratosis and subsequent

impairment of the skin barrier function. This comprehensive analysis aims to elucidate the multifaceted clinical manifestations of this rare dermatological condition, delving into the intricacies of its phenotypic expression, age-dependent variations, and associated complications.<sup>4</sup>

### Skin Changes:

The hallmark clinical feature of ichthyosis vulgaris is the presence of dry, scaly skin with a fish-like appearance, hence the term "ichthyosis." This scaly presentation typically emerges within the first year of life and becomes more prominent as the individual grows. The scales are often fine, adherent, and white or grayish in color. They tend to accumulate predominantly on the extensor surfaces of the limbs, such as the elbows and knees, as well as the trunk and face.<sup>4</sup>

### Pruritus:

Pruritus, or itching, is a common and distressing symptom associated with ichthyosis vulgaris. The dry, scaly skin can lead to significant discomfort and can impact the individual's quality of life. The severity of pruritus can vary widely among patients, ranging from mild itching to intense, debilitating discomfort. Scratching may exacerbate skin damage and contribute to secondary complications.<sup>4</sup>

### Palmoplantar Changes:

The palms and soles of individuals with ichthyosis vulgaris often exhibit distinctive features. These areas may develop hyperlinearity, with prominent creases and fissures. Thickening of the skin on the palms and soles, known as hyperkeratosis, can result in painful fissures, limiting manual dexterity and ambulation in severe cases.<sup>4</sup>

### Variable Phenotypic Expression:

One striking aspect of ichthyosis vulgaris is its variable phenotypic expression. While some individuals may only experience mild scaling and pruritus, others may present with more severe manifestations, including deep fissures, erythroderma (generalized redness), and a heightened risk of secondary bacterial infections. The age at onset and progression of symptoms can also differ among affected individuals.<sup>4,5</sup>

### Complications:

Complications associated with ichthyosis vulgaris may arise due to impaired skin barrier function. These complications can include skin infections, such as bacterial folliculitis and cellulitis, as well as exacerbation of pre-existing conditions like atopic dermatitis (eczema). Additionally, the cosmetic impact of the condition can lead to psychosocial distress and reduced quality of life, especially in cases with more pronounced clinical features.<sup>5,6</sup>

## DIAGNOSIS OF ICHTHYOSIS VULGARIS

The diagnosis of ichthyosis vulgaris, a rare hereditary disorder of keratinization, necessitates a comprehensive evaluation that combines clinical assessment, genetic analysis, and laboratory investigations. This in-depth analysis aims to elucidate the multifaceted diagnostic approach to this

## Pathophysiological Insights and Therapeutic Approaches in Ichthyosis Vulgaris: A Comprehensive Review

dermatological condition, encompassing the clinical presentation, histopathological findings, and genetic testing modalities.<sup>6</sup>

### CLINICAL EVALUATION

**Patient History:** The diagnostic journey typically commences with a thorough patient history. Inquiring about the onset and progression of skin symptoms, including the presence of dry, scaly skin and pruritus, is essential. Additionally, obtaining a detailed family history to identify potential hereditary patterns is crucial.<sup>6</sup>

**Physical Examination:** A meticulous physical examination is central to the diagnosis of ichthyosis vulgaris. Dermatologists scrutinize the skin for characteristic features, such as fine, adherent scales, particularly in the extensor surfaces of the limbs, trunk, and face. Distinctive palmoplantar changes, including hyperlinearity and hyperkeratosis, may also be evident.<sup>6,7</sup>

### Histopathological Examination

In challenging cases or for confirmation of the diagnosis, a skin biopsy may be performed. Histopathological analysis of skin tissue can reveal specific features consistent with ichthyosis vulgaris. These include hyperkeratosis (thickening of the outermost layer of the skin), a diminished or absent granular layer, and alterations in the stratum corneum.<sup>7</sup>

### Genetic Testing

Molecular genetic testing plays a pivotal role in confirming the diagnosis of ichthyosis vulgaris and identifying the underlying genetic mutations responsible for the condition. The filaggrin gene (FLG) is the primary culprit, and sequencing techniques can uncover pathogenic variations within this gene. Genetic testing is particularly valuable in cases with atypical clinical presentations or to confirm the diagnosis definitively.<sup>8</sup>

### Differential Diagnosis

Distinguishing ichthyosis vulgaris from other forms of ichthyosis and dermatological conditions with overlapping features is essential. The differential diagnosis may include disorders such as X-linked ichthyosis (XLI), epidermolytic ichthyosis, and acquired ichthyosis, among others. Clinical acumen, histopathological findings, and genetic testing are all instrumental in resolving diagnostic dilemmas.<sup>8</sup>

Diagnosing ichthyosis vulgaris necessitates a multidimensional approach that encompasses clinical evaluation, histopathological examination, and genetic testing. The characteristic clinical features, coupled with histopathological findings consistent with hyperkeratosis, and the identification of pathogenic mutations in the filaggrin gene (FLG), collectively form the diagnostic cornerstone for this rare dermatological disorder. Additionally, a comprehensive differential diagnosis is imperative to rule out other ichthyotic conditions and ensure accurate diagnosis and management. The synergy of clinical expertise and advanced diagnostic modalities continues to enhance our capacity to

identify and characterize ichthyosis vulgaris, facilitating targeted therapeutic interventions and personalized patient care.<sup>9</sup>

### Treatment Strategies for Ichthyosis Vulgaris

Ichthyosis vulgaris, a hereditary disorder characterized by impaired epidermal differentiation and the formation of dry, scaly skin, poses a therapeutic challenge for clinicians. Effective management of this condition necessitates a comprehensive approach that addresses the underlying pathophysiology, alleviates symptoms, and enhances the patient's quality of life. This comprehensive analysis aims to explore the multifaceted treatment strategies available for individuals affected by ichthyosis vulgaris, encompassing topical therapies, emollients, and emerging therapeutic modalities.<sup>10</sup>

### EMOLLIENTS AND TOPICAL THERAPIES

**Emollients:** The cornerstone of managing ichthyosis vulgaris is the regular use of emollients. Emollients, such as moisturizing creams and ointments, serve to hydrate the skin and restore the disrupted skin barrier. These should be applied liberally and frequently, especially after bathing, to trap moisture and prevent excessive water loss through the skin.<sup>10</sup>  
**Keratolytics:** In cases with thicker scales and hyperkeratosis, keratolytic agents may be employed to promote the shedding of dead skin cells. These agents can include urea-based creams or alpha hydroxy acids. However, caution should be exercised to avoid overuse, which may exacerbate skin irritation.<sup>10</sup>

**Topical Retinoids:** In certain instances, topical retinoids, such as tretinoin, may be prescribed to enhance epidermal turnover and reduce scaling. However, these medications should be used judiciously, as they can be irritating to the skin.<sup>10</sup>

**Topical Steroids:** For individuals experiencing inflammation and pruritus, topical steroids may be recommended on a short-term basis to alleviate symptoms. Careful monitoring is essential to prevent side effects associated with prolonged use.<sup>11</sup>

### BATHING AND HYDRATION

**Bathing Practices:** Individuals with ichthyosis vulgaris should adopt gentle bathing practices, avoiding hot water and harsh soaps, which can exacerbate skin dryness. Lukewarm baths with emollient-rich bath oils can be beneficial. Additionally, the use of mild, fragrance-free cleansers is advisable.<sup>11</sup>

**Humidification:** Employing humidifiers in the home environment, especially during dry seasons or in regions with low humidity, can help maintain skin moisture levels and alleviate symptoms.<sup>12</sup>

### COMPLICATIONS MANAGEMENT

**Infection Control:** Vigilance is essential to prevent secondary skin infections. Prompt treatment of bacterial or fungal

## Pathophysiological Insights and Therapeutic Approaches in Ichthyosis Vulgaris: A Comprehensive Review

infections, if they arise, with appropriate antibiotics or antifungal agents is imperative.<sup>12</sup>

**Pruritus Management:** Addressing pruritus (itching) is a critical component of treatment. Antihistamines or other anti-itch medications may be prescribed to alleviate discomfort and prevent excessive scratching, which can worsen the condition.<sup>13</sup>

### EMERGING THERAPIES

**Gene Therapy:** Research into gene therapy approaches for ichthyosis vulgaris is ongoing. Gene replacement strategies aim to correct the underlying genetic mutations responsible for the condition, offering potential long-term solutions.<sup>13</sup>

**Biologic Therapies:** Biologic therapies, such as monoclonal antibodies targeting specific inflammatory pathways, are under investigation for their potential in managing ichthyosis vulgaris, particularly in severe and refractory cases.<sup>14</sup>

The treatment landscape for ichthyosis vulgaris encompasses a diverse array of strategies, ranging from emollients and topical therapies to emerging therapeutic modalities like gene therapy and biologic agents. Tailoring treatment to the individual's clinical presentation and addressing complications promptly are integral aspects of management. A multidisciplinary approach, involving dermatologists, geneticists, and supportive care teams, is often necessary to optimize the care of individuals affected by this challenging dermatological disorder. Ongoing research and collaboration hold promise for further advancing the management and ultimately improving the quality of life for those living with ichthyosis vulgaris.<sup>15,16</sup>

### CONCLUSION

In the realm of dermatology, ichthyosis vulgaris stands as a compelling testament to the intricate interplay between genetic predisposition, skin physiology, and clinical manifestation. This comprehensive exploration of ichthyosis vulgaris has illuminated the multifaceted nature of this hereditary disorder, from its underlying genetic determinants to its clinical presentation and the evolving landscape of therapeutic interventions.

**Genetic Underpinnings:** At its core, ichthyosis vulgaris is a genetic disorder with a well-defined molecular basis. Mutations in the filaggrin gene (FLG), encoding a pivotal protein in epidermal differentiation and skin barrier function, underlie the pathophysiology of this condition. Understanding the genetic landscape of ichthyosis vulgaris has not only allowed for precise diagnosis through genetic testing but has also paved the way for innovative gene-based therapeutic strategies, heralding hope for future treatments.

**Clinical Spectrum:** The clinical spectrum of ichthyosis vulgaris is marked by considerable variability, ranging from mild skin scaling and pruritus to more severe manifestations characterized by deep fissures, erythroderma, and heightened susceptibility to secondary infections. This clinical heterogeneity underscores the importance of personalized

management tailored to the unique needs of each patient, with emollients, topical therapies, and adjunctive measures serving as pivotal components of care.

**Emerging Therapies:** The horizon of ichthyosis vulgaris management is adorned with promise, as novel therapeutic modalities continue to emerge. Gene therapy, with its potential to correct underlying genetic mutations, offers a glimpse into a future where the disorder's root cause can be directly addressed. Biologic therapies, honed to modulate inflammatory cascades, may revolutionize the treatment landscape, particularly in refractory cases.

**Challenges and Uncharted Territories:** However, it is crucial to acknowledge the persisting challenges in the realm of ichthyosis vulgaris. The variable natural history of the disorder, coupled with its impact on the patient's quality of life, necessitates ongoing research to refine diagnostic tools, optimize therapeutic regimens, and enhance the understanding of the disease pathogenesis.

**Holistic Care:** Furthermore, the management of ichthyosis vulgaris transcends the clinical sphere, necessitating a holistic approach. Psychosocial support, patient education, and a collaborative, multidisciplinary care model are integral elements in the comprehensive care paradigm, aiming to mitigate the psychosocial impact of the disorder and improve patients' overall well-being.

**Collaboration and Research:** In this journey, collaboration among dermatologists, geneticists, researchers, and patient advocacy groups remains pivotal. The concerted efforts of these stakeholders are vital in unraveling the complexities of ichthyosis vulgaris, advancing diagnostic precision, and ushering in innovative therapies.

**Conclusion of Hope:** In conclusion, ichthyosis vulgaris is a rare dermatological disorder that has intrigued and challenged the medical community for generations. While its pathogenesis remains intricate, recent advances in genetics and therapeutics have illuminated a path forward. With continued research, innovation, and a commitment to patient-centric care, we stand poised to offer brighter prospects to individuals living with ichthyosis vulgaris, ultimately transforming their journeys from one of adversity to one of hope.

### REFERENCES

- I. Oji V, Traupe H. Ichthyosis: clinical manifestations and practical treatment options. *Am J Clin Dermatol.* 2009;10(6):351–364. doi: 10.2165/11311070-000000000-00000.
- II. Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, McLean WH, et al. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. *Br J Dermatol.* 2009;161(4):884–889. doi: 10.1111/j.1365-2133.2009.09339.x.

## Pathophysiological Insights and Therapeutic Approaches in Ichthyosis Vulgaris: A Comprehensive Review

- III. Oji V, Tadani G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. *J Am Acad Dermatol.* 2010;63(4):607–641. doi: 10.1016/j.jaad.2009.11.020.
- IV. Dreyfus I, Pauwels C, Bourrat E, Bursztejn AC, Maruani A, Chiaverini C, et al. Burden of inherited ichthyosis: a French national survey. *Acta Derm Venereol.* 2015;95(3):326–328. doi: 10.2340/00015555-1955.
- V. Schmuth M, Gruber R, Elias PM, Williams ML. Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. *Adv Dermatol.* 2007;23:231–256. doi: 10.1016/j.yadr.2007.07.011.
- VI. Kuramoto N, Takizawa T, Matsuki M, Morioka H, Robinson JM, Yamanishi K. Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1. *J Clin Invest.* 2002;109(2):243–250. doi: 10.1172/JCI0213563.
- VII. Ishida-Yamamoto A, Igawa S. The biology and regulation of corneodesmosomes. *Cell Tissue Res.* 2015;360(3):477–482. doi: 10.1007/s00441-014-2037-z.
- VIII. Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. *Biochim Biophys Acta.* 2014;1841(3):280–294. doi: 10.1016/j.bbalip.2013.11.007.
- IX. Raymond AA, Gonzalez de Peredo A, Stella A, Ishida-Yamamoto A, Bouyssie D, Serre G, et al. Lamellar bodies of human epidermis: proteomics characterization by high throughput mass spectrometry and possible involvement of CLIP-170 in their trafficking/secretion. *Mol Cell Proteomics.* 2008;7(11):2151–2175. doi: 10.1074/mcp.M700334-MCP200.
- X. Elias PM, Williams ML, Maloney ME, Bonifas JA, Brown BE, Grayson S, et al. Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. *J Clin Invest.* 1984;74(4):1414–1421. doi: 10.1172/JCI111552.
- XI. Sato J, Denda M, Nakanishi J, Nomura J, Koyama J. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. *J Invest Dermatol.* 1998;111(2):189–193. doi: 10.1046/j.1523-1747.1998.00244.x.
- XII. Hoppe T, Winge MC, Bradley M, Nordenskjöld M, Vahlquist A, Berne B, et al. X-linked recessive ichthyosis: an impaired barrier function evokes limited gene responses before and after moisturizing treatments. *Br J Dermatol.* 2012;167(3):514–522. doi: 10.1111/j.1365-2133.2012.10979.x.
- XIII. Winge MC, Hoppe T, Berne B, Vahlquist A, Nordenskjöld M, Bradley M, et al. Filaggrin genotype determines functional and molecular alterations in skin of patients with atopic dermatitis and ichthyosis vulgaris. *PLoS One.* 2011;6(12):e28254. doi: 10.1371/journal.pone.0028254.
- XIV. Sturesdotter Hoppe T. Skin barrier function and mRNA expression profiles in patients with atopic dermatitis, ichthyosis vulgaris, and X-linked recessive ichthyosis: aetiopathogenic differences and the impact of moisturizing treatment. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Medicine, ISSN 1651-6206; 859. Uppsala: Uppsala University; 2013.
- XV. Paller AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. *J Allergy Clin Immunol.* 2017;139(1):152–165. doi: 10.1016/j.jaci.2016.07.019.
- XVI. Khnykin D, Ronnevig J, Johnsson M, Sitek JC, Blaas HG, Hausser I, et al. Ichthyosis prematurity syndrome: clinical evaluation of 17 families with a rare disorder of lipid metabolism. *J Am Acad Dermatol.* 2012;66(4):606–616. doi: 10.1016/j.jaad.2011.04.014.